Multiple Sclerosis Trials
ANA Has Treated Over 100 Patients with New Alzheimer’s Disease Medication
Denied Alzheimer’s Coverage: The Uphill Battle Against Insurance Companies
Dr. Weisman and His Patients Featured in Article About MCI
ANA Featured in Washington Post Article About Leqembi
Dr. Weisman Quoted in Article about Quest Rapid Alzheimer’s Test
An Open Letter to Highmark and Independence Blue Cross
FDA Converts Lecanemab to Traditional Approval
Dr. Weisman Quoted in Philadelphia Inquirer Article about Tofersen
FDA Gives Accelerated Approval to New ALS Treatment
Statement of inclusion
Abington Neurological Associates is proud to offer clinical trials investigating potential treatments in AD. Alzheimer’s is a terrible, fatal disease, which currently has no disease modifying treatment, and affects people of all creeds, nationalities and ethnicities. We welcome any individual with Alzheimer’s disease into these trials and will continue to do so. In previous trials, we are pleased to have contributed data from traditionally under-diagnosed and under-studied minority populations. ANA is committed to recruiting subjects until AD is cured.
Joining a trial is a highly personal decision. Aside from long lists of exclusion criteria, trials are not the right fit for everyone or for every family. Culture does play a role in this decision making. We aim to remove the barriers we can.